Press Release

4,710 Clinical Trials By Massachusetts Research Centers

PhRMA November 6, 2013


Worcester, MA (November 12, 2013) – Working with Massachusetts research institutions, including several facilities in Worcester, the nation’s biopharmaceutical research companies have conducted 4,710 clinical trials of new medicines in the state over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The report, “Research in Your Backyard:  Pharmaceutical Clinical Trials in Massachusetts,” shows biopharmaceutical companies continuing to expand clinical research with over 700 trials added throughout the state in the last 1.5 years.   

In Worcester, the companies and local research collaborators have conducted 491 new medicine trials since 1999, including 38 that target cancer, diabetes, heart disease and stroke that are still active and recruiting patients.  Eighty-four trials have been added in Worcester since 2012.

The new report was released today by PhRMA and the Worcester Regional Chamber of Commerce at a news conference.  Conference speakers included former Massachusetts Lt. Gov. Tim Murray, the new president and CEO of the Worcester Regional Chamber of Commerce, Dr. Margaret Koziel, a senior clinical researcher at the University of Massachusetts Medical School, Jack Whelan, the survivor of a rare blood cancer, a Leukemia & Lymphoma Society volunteer and strong advocate of clinical trials and research, and PhRMA spokesman Jeff Trewhitt, co-author of the report.   

“Clinical research in central Massachusetts allows our researchers to be involved in the development of important new medicines for patients,” said Murray.  “Clinical trials have benefited such institutions as the UMass Medical School, Reliant Medical Group at Worcester Medical Center and Saint Vincent Hospital.”

“Our companies have been a source of jobs, investment in research and contributions to local communities throughout Massachusetts,” said Trewhitt.  “In 2011, the biopharmaceutical research sector supported more than 179,000 high-quality jobs in the state and generated $38 billion in economic activity.  The more than 50,000 employees who work directly for biopharmaceutical companies in Massachusetts alone paid $173 million in state taxes.” 

More than half of the clinical trials conducted in the Bay State by biopharmaceutical companies and their local collaborators have targeted the most debilitating chronic diseases – cancer, diabetes, heart disease, stroke, asthma and mental illnesses.  Over 500 of those chronic condition trials are still active in communities all over the state, including Boston, Worcester, Springfield, Framingham, Quincy, Cambridge, Lawrence, Pittsfield, Brockton, Fall River, Haverhill, Milford, Newton and Hyannis.

Of 38 trials of potential new medicines still active in Worcester and seeking patients, 29 are for cancer, four are for heart disease, three for stroke and two for diabetes. 

In addition to institutions in Worcester, biopharmaceutical companies are partnering with a wide range of university medical schools and science centers, local hospitals and contract research organizations in other parts of the state, including:

  • Boston University’s Alzheimer’s Disease Center.
  • Tufts University Medical Center, Boston.
  • Massachusetts General Hospital, Boston.
  • Metrowest Medical Center, Framingham.
  • Cape Cod Hospital, Hyannis.
  • Baystate Medical Center, Springfield.
  • New England Center for Clinical Research, Fall River.
  • Quincy Medical Center Alzheimer’s Disease Center.
  • Berkshire Medical Center, Pittsfield.
  • Lahey Clinic, Burlington.
  • Children’s Hospital Boston.
  • McLean Hospital, Belmont. 

More information on clinical trials in Massachusetts can be found at , the comprehensive trials data-base maintained by the National Institutes of Health, and

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit